Palo Alto Medical Foundation

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Palo Alto Medical Foundation sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

Palo Alto Medical Foundation: 11 sponsored US clinical trials, none currently recruiting.

Palo Alto Medical Foundation sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Toxoplasmosis, Cerebral, with 1 trials.

Top-decile sponsor footprint

Palo Alto Medical Foundation ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 67/100

10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED NA

The HOMBRE Trial: Comparing Two Innovative Approaches to Reduce Chronic Disease Risk Among Latino Men

NCT03092960
COMPLETED NA

Research Aimed at Improving Both Mood and Weight

NCT02246413
COMPLETED NA

Culturally Relevant Exercise for Diabetes (CURE-D)

NCT02061618
COMPLETED NA

CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact

NCT02246400
COMPLETED NA

The DASH Diet for Adults With Uncontrolled Asthma

NCT01725945
COMPLETED Phase 2

Can Diet- and Exercise-Induced Weight Loss Improve Asthma Control in Adults?

NCT00901095
COMPLETED Phase 2

Evaluation of Lifestyle Interventions to Treat Elevated Cardiometabolic Risk in Primary Care

NCT00842426
COMPLETED NA

Use of Online Personalized Health Record System to Promote Self-Management of Diabetes

NCT00542204
TERMINATED Phase 2

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
COMPLETED Phase 2

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

NCT00493064
COMPLETED NA

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

NCT00002064

Phase Distribution

PhaseTrial count
Phase 2 4

Therapeutic Areas

Toxoplasmosis, Cerebral 1
HIV Infections 1

How the Palo Alto Medical Foundation early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 10 completed (91%).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Toxoplasmosis, Cerebral (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Palo Alto Medical Foundation: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Palo Alto Medical Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Palo Alto Medical FoundationAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Palo Alto Medical Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Palo Alto Medical Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Palo Alto Medical Foundation page

11 registered trials is a research-attention snapshot, not an endorsement of Palo Alto Medical Foundation or any single study.

  • None of Palo Alto Medical Foundation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Toxoplasmosis, Cerebral is the condition Palo Alto Medical Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Toxoplasmosis, Cerebral trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Palo Alto Medical Foundation pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.